Novo Invests $2bn In Diabetes Franchise Growth
This article was originally published in Scrip
Executive Summary
Danish diabetes drug maker Novo Nordisk launched a Phase IIIa clinical trial program for the oral version of its glucagon-like peptide-1 (GLP-1) analog semaglutide on 26 August and simultaneously revealed plans to invest $2bn in manufacturing to support the potential blockbuster diabetes drug.